Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer

  • Technology appraisal guidance
  • TA1041
  • Published: 
Download guidance (PDF)

2 Information about durvalumab

Marketing authorisation indication

2.1

Durvalumab (Imfinzi, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin is indicated for 'the first-line treatment of adults with extensive-stage small cell lung cancer'.

Dosage in the marketing authorisation

Price

2.3

The list price is £592 for a 120‑mg vial and £2,466 for a 500‑mg vial (excluding VAT; BNF online accessed October 2024).

2.4

The company has a commercial arrangement. This makes durvalumab available to the NHS with a discount. The size of the discount is commercial in confidence.